Aprea Therapeutics News

Aprea Therapeutics' Promising Cancer Drug Candidate Warrants Buy Rating

TipRanksApr 12 11:35 ET

Optimistic Outlook for Aprea Therapeutics' Oncology Pipeline: A Comprehensive Buy Rating Analysis

TipRanksApr 11 06:26 ET

Aprea Therapeutics Announces Presentations on Its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics, Inc. (Nasdaq: APRE) today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA.

GlobeNewswireApr 10 12:00 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ

BenzingaApr 4 08:09 ET

Aprea Therapeutics Files to Sell 4.39M Shares of Common Stock for Holders

Seeking AlphaApr 3 16:30 ET

Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating

TipRanksMar 27 16:05 ET

Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)

TipRanksMar 27 08:20 ET

Aprea Therapeutics Is Maintained at Outperform by Wedbush

Aprea Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesMar 27 08:02 ET

Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow JonesMar 26 11:22 ET

Buy Rating Affirmed: Aprea Therapeutics Poised for Growth With Strong Pipeline Momentum Into 2024

TipRanksMar 26 11:15 ET

Express News | HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target

Moomoo 24/7Mar 26 11:12 ET

Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading

US stocks looked set to open modestly higher Tuesday as investors parsed durable goods and home price data and looked ahead to a key consumer confidence gauge. Dow Jones Industrial Average futures wer

MT NewswiresMar 26 09:29 ET

Aprea Therapeutics: Q4 Earnings Insights

Aprea Therapeutics (NASDAQ:APRE) reported its Q4 earnings results on Tuesday, March 26, 2024 at 07:45 AM.Here's what investors need to know about the announcement.EarningsAprea Therapeutics missed est

BenzingaMar 26 09:10 ET

Aprea Therapeutics GAAP EPS of -$0.92

Seeking AlphaMar 26 08:05 ET

Aprea Therapeutics 4Q Loss/Shr 92c >APRE

Aprea Therapeutics 4Q Loss/Shr 92c >APRE

Dow JonesMar 26 07:45 ET

Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline

TipRanksMar 19 15:05 ET

Karolinska Development's Portfolio Company Aprea Therapeutics Receives FDA IND Approval and Secures Funding of USD 34 Million

STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company's IND application

GlobeNewswireMar 14 07:48 ET

Aprea Therapeutics Secures Funding and Advances Drug Pipeline

TipRanksMar 12 16:43 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersTC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's market cap stands at $4.4 million. Dyadic International (NASDAQ:DYAI) s

BenzingaMar 11 09:05 ET

Market-Moving News for March 11th

DUO: 151% | Fangdd Network shares are trading higher after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sectorMESO: 52% | United States Food

BenzingaMar 11 08:40 ET